Home Business Huakang Medical has passed registration: the first 9 months of revenue of 500 million yuan will be listed as a listed company in Wuhan again_投资_谭平涛_康汇

Huakang Medical has passed registration: the first 9 months of revenue of 500 million yuan will be listed as a listed company in Wuhan again_投资_谭平涛_康汇

by admin

Original title: Huakang Medical passed registration: the first 9 months of revenue of 500 million Wuhan will create another listed company

The China Securities Regulatory Commission disclosed yesterday that, in accordance with legal procedures, the following companies have approved the registration of initial public offerings on the Growth Enterprise Market: Shandong Sanyuan Biotechnology Co., Ltd. and Wuhan Huakang Century Medical Co., Ltd.

The above-mentioned companies and their underwriters will respectively negotiate with the Shenzhen Stock Exchange to determine the issuance schedule and publish prospectus documents one after another.

This means that Huakang Medical has passed the final threshold for listing and is expected to be listed on the Shenzhen Stock Exchange in the near future.

Huakang Medical plans to raise 400 million yuan, of which 99.35 million yuan will be used for technology R&D center upgrade projects, 55.08 million yuan will be used for marketing and operation and maintenance center construction projects, and 250 million yuan will be used to supplement working capital.

Huakang Medical is a comprehensive service provider of modern medical purification systems. It is committed to solving medical infection problems and providing a clean, safe and intelligent medical environment for various hospitals. Its main business includes medical purification system research and development, design, implementation, and operation and maintenance. Sales of related medical equipment and medical consumables.

During the reporting period, Huakang Medical’s main service targets included Wuhan Huoshenshan Hospital, Union Hospital of Tongji Medical College of Huazhong University of Science and Technology, Hubei Provincial People’s Hospital, Zhongnan Hospital of Wuhan University, Zhanjiang Central Hospital of Guangdong Province, and the First Affiliated Hospital of Anhui Medical University , Nanfang Hospital of Guangdong Southern Medical University, etc.

See also  In the US, investigation into the autopilot of 765 thousand Tesla started

The prospectus shows that Huakang Medical’s revenue in 2018, 2019, and 2020 will be 427 million yuan, 600 million yuan, and 762 million yuan, respectively; net profits will be 29.72 million yuan, 58.687 million yuan and 52.6 million yuan respectively.

In the first half of 2021, Huakang Medical’s revenue was 300 million yuan, net profit was 7.83 million yuan, and net profit after deduction was 6.92 million yuan.

During the reporting period, Huakang Medical and its subsidiaries enjoyed tax incentives for high-tech enterprises of 5.216 million yuan, 10.327 million, 8.0392 million and 2.186 million; R&D expenses plus deducted tax incentives were 2.5578 million, 3.5685 million, 4.937 million and 2.492,900. The total income tax benefits accounted for 21.55%, 20%, 22.21% and 50.14% of profits.

Huakang Medical’s revenue in the first nine months of 2021 was 500 million yuan, an increase of 27.3% from 395 million yuan in the same period of the previous year; operating profit was 39.05 million yuan, compared with 3.32 million yuan in the same period last year; net profit after non-deduction was 32.49 million Yuan, compared with 674,400 yuan in the same period last year.

Huakang Medical expects that its operating income for 2021 will be between 959 million yuan and 1 billion yuan, and the net profit attributable to shareholders of the parent company will be between 73 million yuan and 82 million yuan.

Fosun Investment and Sunshine Life are shareholders

Tan Pingtao directly holds 46.70.9 million shares of Huakang Medical, accounting for 58.98% of the total shares of Huakang Medical, and is the controlling shareholder of Huakang Medical; Tan Pingtao’s spouse, Hu Xiaoyan, directly holds 3,123,700 shares of Huakang Medical, accounting for shares of Huakang Medical. 3.94% of the total;

See also  Women's Basketball World Cup qualifiers are determined to be hosted by three cities, including Osaka, Japan_China Women's Basketball

At the same time, Tan Pingtao holds 48.93% of the property share of Kanghui Investment, an employee shareholding platform, and Hu Xiaoyan holds 0.49% of the property share of Kanghui Investment and serves as the executive partner of Kanghui Investment. Tan Pingtao and Hu Xiaoyan indirectly control Huakang through Kanghui Investment. Medical 4,815,400 shares, accounting for 6.08% of Huakang Medical’s total share capital.

Tan Pingtao and his spouse control a total of 54.648 million shares of Huakang Medical, accounting for 69.00% of the total shares of Huakang Medical. Tan Pingtao and Hu Xiaoyan are the actual controllers of Huakang Medical.

Ms. Hu Xiaoyan, born in September 1975, has a high school education. From July 1994 to September 2008, independent business; October 2008, founded Huakang Co., Ltd., from October 2015 to July 2017, served as a director of Huakang Co., Ltd.; in July 2017, resigned as a director of Huakang Co., Ltd., worked at Huakang Century General Manager Office, concurrently serving as the executive partner of Wuhan Kanghui Investment Management Center (Limited Partnership).

In addition, Fosun Investment holds 11.9%, Sunshine Life holds 10%, Fortune Investment holds 5%, and Gimpo Investment holds 4%.

After the IPO, Tan Pingtao directly holds 44.23%, Fosun Investment holds 8.93%, Sunshine Life holds 7.5%, Kanghui Investment holds 4.56%, Fortune Investment holds 3.75%, and Gimpo Investment holds 3%. , Hu Xiaoyan holds 2.96%.

———————————————

Lei Di was founded by Lei Jianping, a senior media person. If reprinted, please indicate the source.Return to Sohu to see more

.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy